1. Home
  2. NOTE vs SCYX Comparison

NOTE vs SCYX Comparison

Compare NOTE & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FiscalNote Holdings Inc.

NOTE

FiscalNote Holdings Inc.

HOLD

Current Price

$1.57

Market Cap

27.5M

Sector

Technology

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$0.59

Market Cap

26.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NOTE
SCYX
Founded
2013
1999
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
27.5M
26.3M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
NOTE
SCYX
Price
$1.57
$0.59
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
1
Target Price
$29.25
$3.00
AVG Volume (30 Days)
248.4K
371.5K
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$102,673,000.00
$2,932,000.00
Revenue This Year
N/A
$167.73
Revenue Next Year
$0.55
$290.78
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.53
$0.57
52 Week High
$24.36
$1.49

Technical Indicators

Market Signals
Indicator
NOTE
SCYX
Relative Strength Index (RSI) 28.50 32.26
Support Level $1.63 $0.58
Resistance Level $1.73 $0.63
Average True Range (ATR) 0.15 0.02
MACD 0.04 -0.00
Stochastic Oscillator 7.84 13.20

Price Performance

Historical Comparison
NOTE
SCYX

About NOTE FiscalNote Holdings Inc.

FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: